Term
| Chronic abdominal pain and altered bowel habits in the absence of any organic cause |
|
Definition
|
|
Term
| ulcerative colitis and crohn's disease |
|
Definition
| inflammatory bowel disease |
|
|
Term
|
Definition
| females affected more commonly, poorly understood and difficult to treat |
|
|
Term
|
Definition
| abdominal pain, altered bowel habits, GERD, nausea, impaired sexual dysfunction, urinary symptoms, fibromyalgia |
|
|
Term
|
Definition
| improvement with defecation, onset associated with a change in frequency of stood, onset associated with change in form of stool |
|
|
Term
|
Definition
| with diarrhea, with constipation, mixed |
|
|
Term
|
Definition
| Anticolinergics/antimuscarinics |
|
|
Term
| Reduce gastric secretion and GI motility |
|
Definition
| Dicyclomine and Hyocyamine |
|
|
Term
| Dicyclomine and Hyoscyamine AEs |
|
Definition
| blurred vision, dry mouth, urinary retention, constipation, tachycardia, dizziness, drowsiness, confusion |
|
|
Term
| considered by the FDA as possibly effective, caution with elderly |
|
Definition
| Chlordiazepoxide/Clidinium |
|
|
Term
| Chlordiazepoxide/Clidinium AE |
|
Definition
| similar to dicyclomine plus benzo side effects |
|
|
Term
| Antidiarrheal for IBS-D -- slows GI motility |
|
Definition
|
|
Term
| Chloride channel activator-- increases intestinal fluid secretion |
|
Definition
|
|
Term
| Recurring episodes of inflammation limited to the mucosal layer of the colon |
|
Definition
|
|
Term
| Transmural inflammation that may affect the entire GI tract |
|
Definition
|
|
Term
|
Definition
| skip lesions rather than continuous disease |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| may increase risk for IBD and exacerbate underlying IBD |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| diseases extends to splenic flexure |
|
|
Term
|
Definition
| beyond splenic flexure but sparing the cecum |
|
|
Term
|
Definition
|
|
Term
|
Definition
| intermittent bloody diarrhea, rectal urgency, tenesmus |
|
|
Term
| feeling that you need to defecate even when bowel is empty |
|
Definition
|
|
Term
|
Definition
| 5-ASA compounds, prednisone, CSA, azathioprine, mercaptopurine, infliximab |
|
|
Term
|
Definition
| often causes sinus tract formation and fistulae |
|
|
Term
|
Definition
| Oral 5-ASA, antibiotics, glucocorticoids, immunomodulators, biologic therapies |
|
|
Term
|
Definition
| Sulfasalazine, Mesalamine |
|
|
Term
| Inhibits COX--> reduced productin of prostaglandins-->reduced colonic inflammation; also inhibits leukotriene synthesis |
|
Definition
|
|
Term
| reaches colon intact, cleaved to sulfapyridine + 5-ASA, use in disease confined to colon |
|
Definition
|
|
Term
|
Definition
|
|
Term
| Released at pH >7 (terminal ileum and colon); useful in UC and ileocecal/colonic CD |
|
Definition
|
|
Term
| Time and pH dependent release from Duodenum to the ileum; indicated for induction of remission and treatment of UC but also useful in diffuse CD |
|
Definition
|
|
Term
| Time and pH dependent release evenly throughout the colon; induction and maintenance of remission in UC |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| once daily dosing advantage |
|
Definition
|
|
Term
| Used when 5-ASA compounds are indadequate |
|
Definition
|
|
Term
|
Definition
| Response usually seen in 7-10 days |
|
|
Term
|
Definition
| GI upset, agitation, insomnia, edema, hyperglycemia |
|
|
Term
|
Definition
|
|
Term
| poor systemic absorption, fewer adverse effects (but expensive!) |
|
Definition
|
|
Term
| metabolite of azathioprine |
|
Definition
|
|
Term
| suppress T-cell activation/antigen recognition |
|
Definition
|
|
Term
|
Definition
| delayed onset (1-4 months), bone marrow suppression, heaptotoxicity and pancreatitis |
|
|
Term
|
Definition
| hepatic fibrosis, bone marrow suppression, pneumonitis |
|
|
Term
|
Definition
| temporary benefit, used in fistulating CD. SE- nephrotoxicity, hepatotoxicity, malignancy |
|
|
Term
|
Definition
| adalimumab, certrolizumab, infliximab, |
|
|
Term
|
Definition
| moderate to severe CD, SC injections |
|
|
Term
|
Definition
| Reduce s/sx and maintain clinical response in moderate to severee CD, fistulizing CD; SC injections |
|
|
Term
|
Definition
| moderate to severe UC or CD, and fistulizting CD; maintains remission of Crohn's given ever 8 weeks; IV dosage form |
|
|
Term
|
Definition
| Active infection, moderate to severe heart failure, untreated TB |
|
|
Term
|
Definition
| HA, nausea, injection site reaction, rash, fatigue |
|
|
Term
| Infliximab increased risk of infection |
|
Definition
| bacterial, mycobacterial, fungal |
|
|
Term
|
Definition
| increased risk for hepatosplenic T-cell lymphoma |
|
|
